Advance the development of SCY-247, a novel antifungal currently in phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula
Active Definitive Contract Awarded Last action
- Contract number
- 75A50126C00007
- Awardee
-
Scynexis Inc. UEI H6PSJYEW3DT9
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $18,454,788
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Solicitation · BAA23100SOL00004 · Posted Sep 26, 2023
- Contract value 9% obligated
-
- $18,454,788.00 Current, with exercised options
- $213,943,726.00 Potential, with all options
- Completion date 1% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Cost No Fee
- Place of performance
- Jersey City, NJ 07302, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Office of the Assistant Secretary for Preparedness and Response (HHS) awarded a $213.9 million definitive contract to Scynexis Inc. on September 15, 2026, for advanced development of SCY-247, a novel antifungal in Phase 1 clinical trials for treatment of invasive candidiasis and prophylaxis of invasive fungal disease in oral and intravenous formulations.
This award carries cost-reimbursement pricing with no fee. The contract ceiling extends to July 31, 2032. Place of performance is Jersey City, New Jersey.
The originating solicitation, posted September 26, 2023, solicits medical countermeasures against chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases through the Biomedical Advanced Research and Development Authority (BARDA). The solicitation encompasses twelve areas of interest including CBRN vaccines, antivirals and antitoxins, antimicrobials for drug-resistant pathogens, diagnostics, influenza therapeutics, and flexible therapeutic platforms. Proposals must meet specified Technology Readiness Level requirements, generally TRL 4 to TRL 6, with comprehensive development plans covering regulatory pathways, manufacturing, clinical strategies, and commercialization. Evaluation prioritizes technical merit and program importance, with secondary consideration of cost realism and past performance. BARDA anticipated multiple awards of various values and contract types. All work must be performed in the United States.
Quick answers
Who was awarded contract 75A50126C00007?
75A50126C00007 was awarded to Scynexis Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 15, 2026.
How much is contract 75A50126C00007 worth?
The government has obligated $18,454,788 on 75A50126C00007. Its potential value, with all options, is $213,943,726.
Was contract 75A50126C00007 competed?
The extent of competition for 75A50126C00007 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award